Por: Associated Press Business October 26, 2022
Biogen delivered a better-than-expected third quarter and hiked its 2022 forecast, as cost cutting continued to help the drugmaker balance sliding sales.The maker of the multiple sclerosis treatment Tecfidera said Tuesday that it chopped research and development costs 22% and also booked a $504 million gain from a building sale as it reduced office space.Total costs and expenses fell 54%, and net income more than tripled to $1.13 billion in the... + full article
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
The Boston Globe USA Business September 27, 2022
LIFE SCIENCESBiogen to pay $900m to settle whistle-blower suit over kickbacksAfter a decade of litigation, Biogen has agreed to pay $900 million to settle a federal whistle-blower lawsuit by a former employee who accused the Cambridge-based drug firm of paying kickbacks to... + más
Biogen pays $900m to settle whistle-blower suit over kickbacks | The Boston Globe
After a decade of litigation, Biogen has agreed to pay $900 million to settle a federal whistle-blower lawsuit by a former employee who accused the Cambridge-based drug firm of paying kickbacks to hundreds of doctors to get them to prescribe its multiple sclerosis drugs. Under... + más
Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe
Orlando Sentinel USA Business September 27, 2022
BOSTON — Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, federal prosecutors said. The agreement announced Monday settles a whistleblower... + más
Biogen pays $900M to settle doctor kickback allegations | ABC News
Fox Business USA Business September 27, 2022
Aflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs. The settlement comes after former Biogen... + más
CNBC USA Health September 27, 2022
In this articleA Biogen facility in Cambridge, Massachusetts.Brian Snyder Reuters will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its drugs, the Justice Department announced on Monday.A former Biogen employee... + más
About iurex | Privacy Policy | Disclaimer |